322 In the index

ACE-031 ACE-031

An engineered protein that was tested in a real clinical trial for a muscle-wasting disease, and it worked in the sense that patients gained noticeable muscle. But the trial was stopped early over safety concerns, including nosebleeds and bleeding gums linked to its effect on blood vessels.

Also known as Ramatercept

Effects Build muscle

Routes Injectable

Legal status Research chemical

WADA Banned at all times

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not established (clinical development discontinued)

Reported range Trial doses up to 3 mg/kg every 2 weeks

Route Subcutaneous injection

Frequency Every 2 weeks (trial protocol)

Duration Trials ran about 6 months before discontinuation

Clinical development halted in 2013 over vascular side effects (nosebleeds, telangiectasia); not approved or legitimately sold. Any current supply is unregulated.

Where this comes from Discontinued Phase I/II clinical trial data (Acceleron Pharma)

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.